title: [Effects of intravenous immunoglobulin and aspirin treatment on the functions of circulating endothelial progenitor cells in children with Kawasaki disease].
abstract: OBJECTIVE
  To study the effects of intravenous immunoglobulin (IVIG) and aspirin treatment on the functions of circulating endothelial progenitor cells (EPCs) in children with Kawasaki disease (KD) and possible mechanisms.
  
  
  METHODS
  Blood samples were obtained in 10 children with KD before and 7 days after the treatment by IVIG and aspirin. MTT method, modified Boyden chamber method and cell culture plate adhesion method were used to assess the functions of EPCs, including proliferation, adhension and migration activities. The plasma levels of tumor necrosis factor-α (TNF-α) and high-sensitivity C reactive protein (hs-CRP) were also measured.
  
  
  RESULTS
  The functions of circulating EPCs 7 days after IVIG and aspirin treatment were significantly improved. IVIG and aspirin treatment significantly reduced plasma TNF-α and hs-CRP concentrations. There was a significant linear regression relationship between the reduced plasma TNF-α and hs-CRP levels and the increased functions of circulating EPCs.
  
  
  CONCLUSIONS
  IVIG and aspirin treatment can improve the functions of circulating EPCs, possibly through reducing plasma concentrations of TNF-α and hs-CRP.
authors.affiliation: Cardiovascular Center, Shenzhen Children's Hospital, Shenzhen, Guangdong 518026, China. nihaomingguo@yahoo.com.cn
authors.forename: Ming-Guo
authors.initials: MG
authors.lastname: Xu
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Men
authors.forename: Ying
authors.initials: Y
authors.lastname: Zu
authors.forename: Chun-Yu
authors.initials: CY
authors.lastname: Zhao
authors.forename: Xiang-Chun
authors.initials: XC
authors.lastname: Meng
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000032:analysis; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000166:cytology / Q000502:physiology*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000188:drug therapy*; D013234:Stem Cells / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D016756:Immunoglobulins, Intravenous; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D001241:Aspirin